Healthcare Equipment and Supplies
Company Overview of CardioKinetix, Inc.
CardioKinetix, Inc. operates as a medical device company that develops catheter-based treatment devices to treat congestive heart failures resulting from a heart attack in patients. The company offers a partitioning device deployed within the left ventricle (for ischemic left sided heart failure patients) that partitions damaged muscles by isolating the non-functional muscle segment from the functional segment; MRI-related heating products; parachute delivery components; percutaneous ventricular restoration therapies; and ventricular restoration products. It serves customers worldwide. The company was incorporated in 2002 and is headquartered in Menlo Park, California.
925 Hamilton Avenue
Menlo Park, CA 94025
Founded in 2002
Key Executives for CardioKinetix, Inc.
Vice President of Operations
Vice President of Clinical
Compensation as of Fiscal Year 2014.
CardioKinetix, Inc. Key Developments
CardioKinetix, Inc. Releases Results of a Pooled Analysis Study of Parachute Ventricular Partitioning Device
Sep 16 14
CardioKinetix Inc. announced results of a pooled analysis study of the first-of-its-kind catheter-based Parachute(R) Ventricular Partitioning Device. Twelve-month clinical data from PARACHUTE III, a study of 100 post-market European patients with ischemic heart failure treated consecutively between 2011 and 2013, were presented at the 2014 TCT Conference in Washington, D.C., by Ulrich Schäfer, M.D., cardiology director of the Structural Heart Division at the Heart Center at the University Medical Center Hamburg-Eppendorf, and at the 2014 HFSA Conference in Las Vegas, Nev., by William Abraham, M.D., professor of internal medicine and director of the Division of Cardiovascular Medicine at Ohio State University Medical Center. Parachute had a very high procedural success rate of 97% (97/100). The twelve-month highlights from the data include: Primary safety endpoint yielded a low 7% rate of device- or procedure-related MACCE. Sustained reduction of left ventricle volumes (p < 0.0001) resulting in significant improvements in systolic function and a significant reduction in left atrial volume (p < 0.05) reflected improved diastolic function. NYHA functional class improved or maintained in 80% of patients. Six-minute walk distance improved at follow-up (p < 0.01), with 46% of patients walking an additional 20 meters or more. Rates of death and the combined endpoint of death and repeat hospitalization for heart failure were 9.5% and 26.0%, respectively.
Cardiokinetix Provides Update on Parachute Iv, the Randomized Pivotal U.S. Trial of the Minimally Invasive Parachute Ventricular Partitioning Device for the Treatment of Heart Failure
Jan 8 13
CardioKinetix, Inc. announced the enrollment of the first patients in PARACHUTE IV, the randomized pivotal U.S. trial of the minimally invasive Parachute(TM) Ventricular Partitioning Device for the treatment of heart failure. PARACHUTE IV is a multi-center pivotal trial designed to evaluate the PARACHUTE implant vs. optimal medical therapy (randomized 1:1) in approximately 500 patients with ischemic heart failure at up to 65 centers. The event-driven primary endpoint includes all-cause mortality and hospitalization for worsening heart failure. Other key endpoints include functional outcomes, quality of life, and hemodynamic measures by echocardiography. The first implant with the Parachute device was performed by David Mego, M.D., assistant medical director at Arkansas Heart Hospital in Little Rock, Arkansas, who treated a 39-year-old female with NYHA class III heart failure referred by Carl Leding, M.D., director of the Congestive Heart Failure Clinic at Arkansas Heart Hospital.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries